Cutting the duration of oxaliplatin-based therapy to three months for patients with advanced colon cancer reduces the risk of peripheral sensory neuropathy without reducing efficacy, a clinical trial shows.

Adjuvant capecitabine plus oxaliplatin (CAPOX) or modified fluorouracil, leucovorin and oxaliplatin (FOLFOX) chemotherapy — the standard of care for patients with stage-III colon cancer following surgery — can trigger peripheral sensory neuropathy, leading to treatment modification or discontinuation.